The FDA and an ALS Treatment

Few diseases are as ferociously debilitating as Amyotrophic Lateral Sclerosis (ALS). But a Food and Drug Administration advisory committee this week gave patients a glimmer of hope by endorsing a new treatment that may slow their decline and provide valuable more time to live.

ALS or Lou Gehrigdisease, is a neurodegenerative disease that gradually deprives people of their ability to function. It affects approximately 30,000 patients in the US with 5,000 new cases each year. Patients typically live only two years after diagnosis because they lose their ability to control key muscle movements and eventually chew and breathe. The FDA and an ALS Treatment

Alley Einstein is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button